NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. NICE Clinical Guideline 67: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease NICE recommends using simvastatin 40 mg as […]
Category Archives: Cardiovascular disease
NPC Archive Item: Reducing blood pressure is beneficial in people with hypertension regardless of age
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; […]
NPC Archive Item: MHRA issue drug alert for Clexane®
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The Medicines and Healthcare products Regulatory Agency (MHRA) have issued advice to healthcare professionals about heparin enoxaparin sodium (Clexane®) pre-filled syringes. The manufacturer of this low molecular weight heparin […]
NPC Archive Item: Treating hypertension in the elderly reduces mortality
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Becket NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358. Published 31st March 2008 (10.1056/NEJMoa0801369) […]
NPC Archive Item: No benefit from rosuvastatin in heart failure
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Kjekshus J et al. Rosuvastatin in older patients with systolic heart failure. NEJM 2007; 357: 2248-61 (CORONA study) In this study in people with moderate to severe heart failure, […]
NPC Archive Item: Potential for confusion with new formulation of Coversyl®
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Servier has announced that their branded versions of perindopril erbumine, (Coversyl® and Coversyl Plus®), also known as perindopril tert-butylamine, have been discontinued and replaced with a different salt called […]
NPC Archive Item: ACE-I plus ARB misses the target
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The ONTARGET investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. New Engl J Med 2008; 358; 1547-59 What is the background to this? ACE-inhibitors […]
NPC Archive Item: What does ENHANCE tell us about the place in therapy of ezetimibe▼?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Kastelein JJP et al. Simvastatin with or without ezetimibe in familial hypercholesterolaemia. New Engl J Med 2008; 358: 1431-1443 (The ENHANCE study 3rd April 2008) The short answer to […]
NPC Archive Item: NPC Podcast – 15th April 2008
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 3 new studies on CV disease that have received a lot of media attention but SHOULDNT change our practice – ENHANCE (ezetimibe); CORONA (rosuvastatin); ONTARGET (ACE/ARBs) [podcast]http://www.npc.nhs.uk/podcast/NPCiPodcast_15thApril08.mp3[/podcast] Subscribe to […]
NPC Archive Item: Digoxin may increase mortality in atrial fibrillation
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Gjesdal K, Feyzi J, Olsson SB. Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data. Heart 2008;94:191–6 What is the background to […]